Athenex, Inc. (ATNX) Research Coverage Started at Laidlaw
Several other research firms also recently commented on ATNX. Deutsche Bank AG began coverage on shares of Athenex in a report on Monday, July 10th. They issued a buy rating and a $20.00 target price on the stock. Credit Suisse Group assumed coverage on shares of Athenex in a research note on Monday. They set an outperform rating and a $25.00 price target on the stock. Finally, Royal Bank Of Canada assumed coverage on shares of Athenex in a research note on Thursday, September 14th. They set an outperform rating and a $35.00 price target on the stock.
Athenex (NASDAQ ATNX) opened at 17.47 on Tuesday. The company’s 50 day moving average is $16.18 and its 200 day moving average is $16.51. The company’s market cap is $996.89 million. Athenex has a 12-month low of $11.21 and a 12-month high of $20.79.
Athenex (NASDAQ:ATNX) last released its earnings results on Monday, August 14th. The company reported ($0.88) EPS for the quarter. The firm had revenue of $4.60 million for the quarter. Analysts forecast that Athenex will post ($2.22) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Athenex, Inc. (ATNX) Research Coverage Started at Laidlaw” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2017/09/22/athenex-inc-atnx-research-coverage-started-at-laidlaw.html.
A number of institutional investors have recently added to or reduced their stakes in ATNX. Laurion Capital Management LP purchased a new stake in Athenex during the second quarter valued at $1,600,000. OxFORD Asset Management LLP purchased a new stake in Athenex during the second quarter valued at $956,000. California Public Employees Retirement System purchased a new stake in Athenex during the second quarter valued at $800,000. Vanguard Group Inc. purchased a new stake in Athenex during the second quarter valued at $800,000. Finally, Goldman Sachs Group Inc. purchased a new stake in Athenex during the second quarter valued at $601,000. 0.88% of the stock is currently owned by institutional investors.
Athenex Company Profile
Athenex, Inc is an oncology pharmaceutical company focused on the development and commercialization of therapies for cancer diseases and supportive therapies. The Company’s technology platform is organized into three categories, including Oral Absorption Platform, Src Kinase Inhibitors and Symptom Therapeutics.
Receive News & Stock Ratings for Athenex Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex Inc. and related stocks with our FREE daily email newsletter.